… and efficacy of using tocilizumab as a drug of preference to treat COVID-19 patients. We …
behind using tocilizumab, as well as differences in its use based on the COVID-19 stage and…

… coronavirus disease 2019 (COVID-19). Our aim was to evaluate the efficacy of tocilizumab in
the management of hospitalized COVID-19 … studies of tocilizumab in hospitalized COVID-19 …

… We identified a total of 84 patients who received tocilizumab and 190 patients who were
treated without the use of tocilizumab as part of COVID-19 management in our hospital. After the …

… In our multicentre, retrospective study of 544 patients with severe COVID-19 pneumonia, the
use of tocilizumab administered either intravenously or subcutaneously was associated with …

… In this study, we report preliminary data from our experience with TCZ administration in
COVID-19 patients hospitalized in a Regional Referral Hospital in the Lombardy region, Italy. …

… Administration of tocilizumab was not associated with relevant … of administration of
tocilizumab in patients with COVID-19 pneumonia. A strategy involving tocilizumab administration …

… the IL-6 inhibitor tocilizumab, we hypothesized that early (pre-emptive) intervention with
tocilizumab might beneficially alter the course of Covid-19. We postulated that tocilizumab would …

… On this basis, physicians at our hospitals have administered Tocilizumab to COVID-19
patients with severe respiratory impairment off-label and outside of a clinical trial hoping to …

… COVID-19, hypoxemia, and at least two of four markedly elevated markers of inflammation
(interleukin-6, C-reactive protein, ferritin, and/or D-dimer) were randomized for tocilizumab (…

… .63, 64 The World Health Organization (WHO) 65 and the Infectious Diseases Society of
America (IDSA) 66 both recommend that tocilizumab only be administered within the context of …